Read our latest news, and find more about us and our portfolio companies.
Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline With funding round by M Ventures, Safar Partners and Horizons Ventures Concerto progresses vision to reinvent humanity’s relationship with microbes
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines • Financing led by M Ventures alongside other new investors JJDC, Pfizer Ventures and British Patient Capital, and including founding investor Oxford Science Enterprises • Nucleome’s pioneering platform seeks to identify direct genetic linkages to disease-associated genes for drug discovery • Funds will advance Nucleome’s autoimmune disease programmes and fuel expansion of its dark genome atlas
Future Fertility's AI-powered oocyte-assessment tools receive CE Mark under the new European Union Medical Device Regulation (MDR)
Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Brian Wong as a member of its Board of Directors.
Tignis, a technology innovator in AI process control for semiconductor manufacturing, today announced it has received Series A funding from M Ventures, the strategic corporate venture arm of Merck, KGaA, Darmstadt, Germany—a leading science and technology company. This investment brings Tignis’ total Series A funding received in 2022 to $10 million. Tignis was introduced to M Ventures through the SEMI Startups for Semiconductor Sustainability program.
Metalenz metasurfaces are now on the market through its partnership with STMicroelectronics, marking the introduction of this revolutionary optical technology in real-world devices
Scipio bioscience has been selected by the @European Innovation Council for a €2.5M grant to pursue their efforts toward the next generation of single-cell tools
Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies
Future Fertility today announced that Christine Prada has been named as Chief Executive Officer. Her employment with Future Fertility will commence in early May.
Electroninks, Inc., today announced the production-scale availability of its full suite of proprietary metal organic decomposition (MOD) conductive metal ink solutions. In addition to bringing standalone ink products to market, Electroninks is also bringing total solutions to the customer with its line of ink products, including its own small (desktop) prototype additive manufacturing solution for rapid on-demand printed circuit board (PCB) printing and repair, called CircuitJet.
SynSense, announced that it will advance the integration of neuromorphic chips and smart cockpits and explore related fields with BMW. This marks the entry point for the application of SynSense’s brain-like technology into smart cockpits
Program participants receive early access to the upcoming release of kits designed to print longer oligos and enable labeling with fluorophores, quenchers, and biotin
iOnctura has preclinical data that shows its autotaxin inhibitor IOA-289 both inhibits pancreatic cells directly and inhibits the cancerpromoting activity of secreted factors from Cancer-Associated Fibroblasts (CAFS)
DNA Script expands worldwide footprint to China, Hong Kong, India, Singapore, South Korea and Taiwan for sales, distribution, and support of enzymatic synthesis products
Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models
Since the pandemic caused a digital transformation for many companies and locked everyone at home, the need for technology suitable to use from home has only increased
Altoida, Inc. raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures and Whitecap Venture Partners
NanoSyrinx has strengthened its management team with the appointment of Dr Marie McAvoy as its Chief Scientific Officer
iOnctura SA will present preclinical data on its next-generation autotaxin inhibitor, IOA-289, at the annual meeting of the American Association for Cancer Research (AACR) taking place on April 8-13, 2022 in New Orleans, Louisiana.
DNA Script’s enzymatic DNA printing on demand technology recognized as no. 3 in the biotech category
Maker of the first-and-only FDA-cleared prescription video game treatment joins the ranks of Canva, Microsoft, SpaceX, and more
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets - NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022
Multi-year, multi-million dollar collaboration will develop new tools to rapidly accelerate the development of RNA-based products, catalyzing a new era in healthcare
Scipio bioscience announces the launch in Europe of Asteria©, its innovative kit for sequencing RNA on individual cells on lab benchtops
Celestial AI’s system transforms computing using light for data movement within and between chips enabling scalability with optical access to memory and compute from single node to exascale systems
Metalenz Inc. today unveiled the GeminiTM product family, switchable illumination optics based on foundational polarization IP
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
First company to develop an AI product to predict egg viability with potential to significantly improve IVF outcomes Financing led by M Ventures with participation from Whitecap Venture Partners